Summary
Gilead Sciences, Inc. (GILD) filed an 8-K on August 2, 2010, to report a significant financing event. On July 26, 2010, the company entered into a purchase agreement to sell $1.1 billion in aggregate principal amount of 1.00% Convertible Senior Notes due 2014 and $1.1 billion in aggregate principal amount of 1.625% Convertible Senior Notes due 2016. The closing of this sale occurred on July 30, 2010, resulting in net proceeds of approximately $2.166 billion after deducting discounts and expenses. These notes are convertible into Gilead's common stock under specific conditions, including a threshold based on stock price performance and the occurrence of certain corporate transactions. The company also entered into convertible note hedge transactions and sold warrants in conjunction with this offering, intended to manage potential dilution. The hedge transactions cost approximately $311.8 million, while the sale of warrants generated proceeds of approximately $132.5 million. This substantial capital raise indicates Gilead's strategic financial maneuvers to fund future operations or acquisitions.
Key Highlights
- 1Gilead Sciences raised approximately $2.166 billion in net proceeds through the sale of two tranches of convertible senior notes: $1.1 billion of 1.00% Convertible Senior Notes due 2014 and $1.1 billion of 1.625% Convertible Senior Notes due 2016.
- 2The notes were sold to initial purchasers (J.P. Morgan Securities Inc., Goldman, Sachs & Co., and Leerink Swann LLC) and subsequently to qualified institutional buyers under Rule 144A, exempt from registration under the Securities Act of 1933.
- 3The 2014 Notes are convertible into common stock at an initial conversion price of approximately $45.08 per share, and the 2016 Notes at approximately $45.41 per share, subject to adjustments.
- 4Conversion of the notes is permitted under specific conditions, including stock price exceeding 130% of the conversion price for 20 trading days in a quarter, specified distributions, corporate transactions, and during the last month before maturity.
- 5Gilead entered into convertible note hedge transactions costing approximately $311.8 million to mitigate potential dilution from note conversions.
- 6The company also sold warrants for approximately $132.5 million, which could result in future dilution if exercised, with strike prices exceeding the then-current market price of Gilead's common stock.
- 7The new notes rank equally with other senior unsecured indebtedness and are effectively subordinated to subsidiary obligations and secured obligations.